Objective To observe the therapeutic effect of Cordyceps Anti-Tuberculosis Capsule combined with chemotherapy on secondary tuberculosis （TB）. Methods Totally 1 205 cases of secondary TB were retrospectively collected. The patients who received chemotherapy were chosen as the control group including 591 cases. The patients who received chemotherapy and Cordyceps Anti-Tuberculosis Capsule were chosen as the treatment group including 614 cases. The naive patients and retreatment patients were treated for 6 months and 9 months respectively in both groups. The efficacy

focus absorption

improvement of main clinical symptoms and sputum conversion were observed. The level of T lymphocyte subsets CD3+

CD4+

CD8+ and CD4+/CD8+ were compared in both groups before and after treatment. Results The total effective rate of the treatment group and control group was 94% and 79% respectively

with a significant difference between groups （P<0.05）. The efficacy of cough

expectoration

fever

chest pain and night sweats or fatigue or hemoptysis in the treatment group was 93.6%

86.6%

75.8% and 96.3% respectively. The efficacy of cough

expectoration

fever

chest pain

night sweats

fatigue and hemoptysis in the control group was 61.3%

53.9%

50.0% and 68.5% respectively. The major symptom improvement in the treatment group was superior to that in the control group （P<0.05 or P<0.01）. The total absorption rate of lung lesions and sputum conversion rate in the treatment group was significantly higher than that in the control group （P<0.05）. Comparing with the control group after treatment

the level of CD3+

CD4+ and CD4+/CD8+ were significantly increased but the CD8+ value was significantly decreased in the treatment group （P<0.05 or P<0.01）. Conclusion The Cordyceps Anti-Tuberculosis Capsule combined with chemotherapy can promote the focus absorption

increase the sputum conversion rate

improve symptoms and enhance the immunity in secondary TB patients

with a better therapeutic effect as compared with western medicine.